DermTech is a commercial stage, genomic based, health technology company with a non-invasive gene expression platform for dermatology. With this platform technology, we are able to analyze skin biopsy samples from an adhesive patch, rather than a scalpel. Our first product is the Pigmented Lesion Assay (PLA), which identifies melanoma associated gene expression. DermTech is currently developing tests to aid the clinical diagnosis of skin cancers and other skin conditions through highly accurate, objective genomic information.
DermTech operates a CLIA licensed laboratory located in the company’s La Jolla, CA headquarters.